AGP Executive Report
Last update: 11 hours agoWeight-loss drug outlook: Novo Nordisk’s tablet version of Wegovy is gaining traction, but investors are uneasy as key semaglutide patents are set to expire in the early 2030s. EV health data (Austria-linked): An Austria-based firm, AVILOO, has launched the world’s largest independent used-EV battery health study, showing big differences in battery ageing between models and even between cars of the same model. Heart failure risk markers: A new study highlights that the neutrophil-percentage-to-albumin ratio can outperform high-sensitivity CRP for predicting mortality in acute heart failure. Clinical research methods: Researchers warn that clinical prediction models can be unstable, meaning individual risk estimates may shift across samples even when the same approach is used. Infectious disease watch: ECDC reports “mud fever” (dermatophilosis) cases in humans across several EU countries, with clusters linked to close physical contact. Long COVID patents: AIM ImmunoTech says new European and UK patent protections for Ampligen in Long COVID will run through June 2041. Austria policy/legal: The American Bar Association adopted new policies on professional independence and related legal education and law-enforcement issues.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
